Acute pharyngitis market seen reaching $4.25 billion by 2030

The acute pharyngitis market is projected to rise from $2.89 billion in 2025 to $3.13 billion in 2026, with The Business Research Company forecasting $4.25 billion by 2030. Rising influenza and respiratory infections, along with telemedicine and online pharmacy adoption, are expected to drive demand.

Why it matters: - The acute pharyngitis market is growing alongside broader respiratory illness trends, which could lift demand for diagnosis, treatment and related care services. - The forecast points to steady expansion through 2030, signaling opportunity for drug makers, telehealth providers and pharmacy channels.

What happened: - The Business Research Company released its "Acute Pharyngitis Market Global Market Report 2026" covering market size, trends and forecasts for 2026-2035. - The report says the market will grow from $2.89 billion in 2025 to $3.13 billion in 2026. - The report projects the market will reach $4.25 billion by 2030. - North America held the largest share of the market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Acute pharyngitis is inflammation of the pharynx, the throat area behind the mouth and nasal passages. - Common symptoms include sore throat, fever, headache and swollen lymph nodes. - Viral infections are the most frequent cause, though bacteria and fungi can also trigger the condition. - The report links historical growth to widespread viral and bacterial pharyngitis, limited awareness of treatment, improved healthcare infrastructure, rising outpatient visits and better access to pharmaceuticals. - The report cites new antiviral and antibiotic drugs, greater telemedicine use, online pharmacy growth, interest in herbal and alternative remedies, and expansion of homecare and specialty care services as future growth drivers. - The report says increasing influenza prevalence is a key market driver. - CDC data showed clinical lab tests positive for influenza reached 31.6% by February 2025, up from 29.4% the prior week and 18.6% at the start of the year. - The report says broader respiratory infection prevalence is also increasing demand for acute pharyngitis diagnosis and treatment. - The CDC reported in May 2025 that COPD was the fifth leading cause of death in the U.S. in 2023, with 141,733 fatalities. - The CDC also reported an age-adjusted prevalence of diagnosed COPD of 3.8% among U.S. adults age 18 and older.

Between the lines: - The market outlook suggests acute pharyngitis care is becoming more connected to access channels beyond traditional clinics, especially telemedicine and online pharmacies. - The growth narrative is being supported by seasonal and chronic respiratory disease burdens, which can increase patient volumes and treatment demand. - The report's regional lead for North America suggests the region may remain the most commercially important market through the current forecast period.

What's next: - The report expects the market to continue expanding at an 8.0% CAGR through 2030. - The Business Research Company says future report updates include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - More information is available in the full report and the sample request.

The bottom line: - Acute pharyngitis is a small but growing market, and the report points to sustained demand as respiratory infections, digital care and pharmacy access expand.